Ibrutinib-induced cardiomyopathy. Issue 1 (2nd January 2019)

• Record Type: Journal Article
• Authors: Kyi, Htay Htay; Zayed, Yazan; Al Hadidi, Samer
• Is Part Of: Journal of community hospital internal medicine perspectives. Volume 9:Issue 1(2019)
• Page Start: 50
• Page End: 52
• Publication Date: 2019-01-02
• Subjects: CLL -- heart failure -- Ibrutinib -- Leukemia -- side effects; Internal medicine -- Periodicals; Hospitals -- Periodicals; Hospitals, Community; Internal Medicine; Hospitals; Internal medicine; Periodicals; Periodicals; 610
• DOI: 10.1080/20009666.2018.1555432
• Languages: English
• ISSNs: 2000-9666

Abstract

ABSTRACT: The use of ibrutinib for the treatment of chronic lymphocytic leukemia (CLL) and other hematologic malignancies is blooming. Atrial fibrillation is a known side effect of ibrutinib but cardiomyopathy was not reported previously. We present an 88-year-old man with CLL who was admitted to the hospital with new-onset atrial fibrillation and symptomatic systolic congestive heart failure one month after ibrutinib initiation. Although ibrutinib was discontinued, the patient continues to have a low ejection fraction four months after discontinuation. Ischemic heart disease was ruled out with normal cardiac catheterization. This case highlights a possible new side effect of ibrutinib that needs to be monitored while patients receive this medication.